The technology developed here revolutionizes point-of-care molecular tests, enabling PCR panel equivalent tests at the cost and simplicity level of rapid antigen tests. This advancement has the potential to replace current gold standards in infectious disease testing, dominated by rapid antigen tests and PCR. The secondary patent portfolio holds critical importance due to potential infringement by existing market leaders. The patents within this portfolio could serve as prior art, potentially invalidating those patents. Interested parties would greatly benefit from adopting this more advanced technology, gaining a significant advantage against their competitors, as it has the potential to disrupt their centralized testing business model. Additionally, manufacturers of rapid antigen tests (such as at-home COVID tests) could benefit from this technology, as failure to adopt molecular technology could render rapid antigen testing obsolete in a few years.

Intellectual Property (IP) & Assets for Sale or License

The IP and assets available for sale include:

mFluiDx Omnibus patent portfolio:

• US Application No. 63/579849, ATTY.DOCKET.NO- 4352-P1 US.PRO – Entitled “Consumable microfluidic molecular diagnostic devices, reader systems, roll-to-roll and other methods of manufacturing”; Inventors: Erh-Chia Yeh, Todd Wallis

This is a very extensive omnibus patent, with the PCT draft already finished and designed to be split into 10+ patents. The omnibus PCT draft comprises over 200 pages and holds significantly more weightage than issued patents.

The PCT draft covers multiple elements of mFluiDx, allowing for greater flexibility in licensing and commercialization strategies. The draft discusses SIMPLE chip systems offering on-site molecular diagnostics with PCR-like sensitivity and specificity, enabling concurrent testing of multiple pathogens within minutes at a lower cost compared to traditional PCR testing. These systems utilize a compact design comprising raised portions forming a fluidic circuit between coupled layers.

 mFluiDx Secondary Patent Portfolio:

• Patent Cooperation Treaty Publication no. WO 2015/021425 A1 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
• Chinese Issued Patent no. 105,531,591 – Entitled “Digital fluid sample separation equipment and the method for quantifying sample analysis for a step”
• Chinese Abandoned Patent no. 109,136,062 – Entitled “Digital fluid sample separation equipment and the method for quantifying sample analysis for a step”
• EP Patent no. 3,030,908 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
• U.S. Patent no. 10,589,270 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
• U.S. Patent no. 9,737,888 – Entitled “Proximal degas driven microfluidic ”
• Patent Cooperation Treaty Publication no. WO 2016/044532 A1 – Entitled “Vacuum battery for portable microfluidic pumping”
• EP Patent no. 3,194,073 – Entitled “Vacuum battery for portable microfluidic pumping”
• Chinese Issued Patent no. 106,687,216 – Entitled “Vacuum battery for portable microfluidic pumping”
• U.S. Patent no. 9,970,423 – Entitled “Vacuum battery for portable microfluidic pumping”
• U.S. Patent no. 10,864,517 – Entitled “Vacuum battery for portable microfluidic pumping”

Also for sale or license are all trade secrets, manufacturing equipment, design files, and prototypes related to the IP, of which assets there is considerable depth.